Curi RMB Capital LLC cut its stake in Edwards Lifesciences Co. (NYSE:EW - Free Report) by 93.7% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 23,295 shares of the medical research company's stock after selling 347,136 shares during the quarter. Curi RMB Capital LLC's holdings in Edwards Lifesciences were worth $1,537,000 as of its most recent SEC filing.
Several other hedge funds have also added to or reduced their stakes in EW. Crewe Advisors LLC bought a new stake in Edwards Lifesciences during the 1st quarter worth $28,000. First Community Trust NA purchased a new stake in shares of Edwards Lifesciences in the second quarter valued at about $29,000. Webster Bank N. A. purchased a new position in Edwards Lifesciences in the second quarter worth $39,000. Versant Capital Management Inc boosted its stake in Edwards Lifesciences by 206.3% in the second quarter. Versant Capital Management Inc now owns 484 shares of the medical research company's stock valued at $45,000 after acquiring an additional 326 shares during the last quarter. Finally, HHM Wealth Advisors LLC bought a new stake in Edwards Lifesciences in the 2nd quarter valued at about $55,000. 79.46% of the stock is owned by institutional investors and hedge funds.
Analyst Ratings Changes
EW has been the subject of a number of research reports. Bank of America cut Edwards Lifesciences from a "buy" rating to a "neutral" rating and cut their price objective for the stock from $105.00 to $75.00 in a report on Thursday, July 25th. Royal Bank of Canada cut their target price on Edwards Lifesciences from $85.00 to $75.00 and set an "outperform" rating on the stock in a research note on Tuesday, October 8th. The Goldman Sachs Group lowered their target price on shares of Edwards Lifesciences from $107.00 to $91.00 and set a "buy" rating on the stock in a research note on Friday, July 26th. StockNews.com downgraded shares of Edwards Lifesciences from a "buy" rating to a "hold" rating in a research report on Thursday, July 25th. Finally, UBS Group decreased their price objective on shares of Edwards Lifesciences from $90.00 to $75.00 and set a "neutral" rating on the stock in a research report on Tuesday, September 10th. Seventeen equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. According to MarketBeat, the company currently has an average rating of "Hold" and an average target price of $75.67.
Read Our Latest Report on EW
Insider Buying and Selling
In other Edwards Lifesciences news, VP Daveen Chopra sold 1,250 shares of the firm's stock in a transaction that occurred on Tuesday, August 20th. The shares were sold at an average price of $69.95, for a total transaction of $87,437.50. Following the sale, the vice president now owns 29,333 shares of the company's stock, valued at approximately $2,051,843.35. This trade represents a 4.09 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of the stock in a transaction on Wednesday, November 13th. The shares were sold at an average price of $65.57, for a total transaction of $327,850.00. Following the completion of the transaction, the vice president now directly owns 46,936 shares in the company, valued at $3,077,593.52. This trade represents a 9.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 41,250 shares of company stock valued at $2,744,438 over the last 90 days. Insiders own 1.29% of the company's stock.
Edwards Lifesciences Trading Up 2.4 %
Shares of NYSE EW traded up $1.60 during trading hours on Friday, reaching $67.76. The stock had a trading volume of 7,530,072 shares, compared to its average volume of 4,640,860. The business's fifty day moving average price is $67.44 and its two-hundred day moving average price is $76.24. Edwards Lifesciences Co. has a 52-week low of $58.93 and a 52-week high of $96.12. The firm has a market cap of $39.96 billion, a price-to-earnings ratio of 9.78, a P/E/G ratio of 3.74 and a beta of 1.12. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06.
Edwards Lifesciences (NYSE:EW - Get Free Report) last announced its earnings results on Thursday, October 24th. The medical research company reported $0.67 EPS for the quarter, hitting analysts' consensus estimates of $0.67. Edwards Lifesciences had a net margin of 70.82% and a return on equity of 20.76%. The business had revenue of $1.35 billion during the quarter, compared to the consensus estimate of $1.57 billion. During the same period in the previous year, the company posted $0.59 earnings per share. The firm's revenue was up 8.9% on a year-over-year basis. Analysts expect that Edwards Lifesciences Co. will post 2.57 EPS for the current fiscal year.
Edwards Lifesciences Profile
(
Free Report)
Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.
Read More
Before you consider Edwards Lifesciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Edwards Lifesciences wasn't on the list.
While Edwards Lifesciences currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.